British Association of Dermatologists Guidelines on the Efficacy and Use of Acitretin in Dermatology

The 2010 guidelines from the British Association of Dermatologists on acitretin highlighted its efficacy in treating severe psoriasis, lichen planus, and other dermatological conditions. Acitretin, a synthetic retinoid, was effective in normalizing epidermal cell functions and had immunomodulatory properties. Higher doses (50-75 mg daily) were more effective than lower doses (10-25 mg daily). It was also beneficial in combination therapies with PUVA and UVB, and showed potential in reducing skin cancer risk in organ transplant recipients. However, acitretin had significant side effects, including teratogenicity, mucocutaneous reactions, hepatotoxicity, and hair loss in up to 75% of patients. Regular monitoring of liver function and lipid profiles was advised due to risks of hyperlipidemia and hepatotoxicity. The guidelines recommended against combining acitretin with ciclosporin or methotrexate due to potential severe hepatic toxicity.